HEALTH PEI VALUES Caring We treat everyone with compassion, respect, fairness, and dignity Integrity We collaborate in an environment of trust, communicate with openness and honesty, and are accountable through responsible decision-making Excellence We pursue continuous quality improvement through innovation, integration, and the adoption of evidence-based practices

WHY DOES URINE MATTER TO YOU?

Introduce yourself to your colleagues and share…..

Objectives: - HOW DID WE GET HERE? - LIAISON PROGRAM - CADTH PRODUCTS - EVIDENCE INFORMED DECISIONS - URINE MATTERS #URINE MATTERS- TWITTER

CADTH is a health technology assessment

agency

We inform technology-related decision-making

in health care

How did we get here?

CADTH’S VISION

HEALTH TECHNOLOGY ASSESSMENT INFORMS EVERY HEALTH TECHNOLOGY DECISION.

CADTH’S MISSION TO ENHANCE THE HEALTH OF CANADIANS BY PROMOTING THE OPTIMAL USE OF HEALTH TECHNOLOGIES.

KNOWLEDGE SHARING: A CADTH SERVICE

Evidence Informed Decision Making

.

Commonly Requested Products The following table provides brief descriptions of the products CADTH most commonly produces in response to requests, as well as approximate completion times.

Product Type Description* Approximate turnaround time from point of topic refinement**

Reference list List of the best available evidence with abstracts and links to full-text documents, if available.

5 to 10 business days

Summary of abstracts Summary based on the abstracts of the best available evidence. Includes the abstracts and

links to full-text documents, if available.

15 business days

Summary with critical appraisal Written summary of the evidence from full text

articles, with a critical appraisal and policy implications.

30 business days

Peer-reviewed summary with critical appraisal

Summary of systematically selected evidence with a critical appraisal and policy implications. An

external peer-review is conducted.

Four months

Systematic review and meta-

analysis

A systematic review of the evidence and a meta-

analysis is performed, where appropriate. Authorship includes a content expert, and an

external peer-review is conducted.

4 to 5 months

Rapid health technology

assessment

A systematic review of clinical studies and an

economic component that includes a systematic

review of economic studies, an economic evaluation or a budget impact analysis. It excludes

a review of the health services impact. Authorship includes a content expert, and an external peer-

review is conducted.

5 to 6 months

Environmental Scan Scan of innovative technologies or pan-Canadian

access, reimbursement, or practice issues.

5 to 40 business days

Drug review and formulary

recommendation

Rigorous review of the clinical and cost-

effectiveness of a drug, and a formulary listing recommendation for Canada’s publicly funded

drug plans (excluding Quebec) through CADTH’s Common Drug Review process. Typically,

submissions are received from drug manufacturers; however, the CDR-participating

drug plans may also request a CDR review.

5 to 6 months

Health technology assessment Comprehensive, evidence-based analysis of a

health technology or technologies to support and inform decisions about health policy, purchasing,

service management, and clinical practice. May

include a systematic review of clinical evidence, a systematic review of cost-effectiveness, and

information on the broader impact on patient health and the health care system.

Determined on a case-by-case basis

Optimal use project Project designed to encourage the optimal use of a health technology or technologies by health care

providers, policy-makers, and consumers. May include a systematic review of clinical evidence, a

systematic review of cost-effectiveness, and development of recommendations, supporting

documents, and tools.

Determined on a case-by-case basis

*These products may be tailored to meet the needs and timelines of the requestor and are subject to the

quality and quantity of the published literature.

**The turnaround times are subject to the capacity and ongoing projects at CADTH. Timelines will be

negotiated between a CADTH representative and the requestor at the time of topic refinement.

RAPID RESPONSE • DRUGS

• DIAGNOSTICS

• DEVICES

• SURGICAL AND MEDICAL PROCEDURES

Collaboration.

PARTNERSHIPS REQUIRED.

CADTH ROADSHOW. PANCANADIAN PERSPECTIVES

LAB UTILIZATION-A CADTH ROADSHOW

SAVE THE DATE! Sharing the results.

March 23, 2015 National Webinar

Urine Matters.

UTI CARE PATHWAYS FOR ENHANCED COLLABORATION & ANTIBIOTIC SAFETY IN SENIORS.

Interior Slide

Contributing to the conversation about laboratory test optimization and encouraging it to continue.

What does the evidence say?

Clinical and Cost Effectiveness 1. What is the clinical effectiveness of urine cultures

and sensitivity analysis, urine dipstick testing, or urinalysis for urine testing in asymptomatic residents in long term-care?

2. What is the cost effectiveness of urine cultures and sensitivity analysis, urine dipstick testing, or urinalysis for urine testing in asymptomatic residents in long-term care?

20

Evidence-based Guidelines 3. What are the evidence-based guidelines regarding

the ordering of urine cultures and sensitivity tests, dipstick tests, and urinalysis for residents in long-term care?

4. What are the evidence-based guidelines regarding proper collection of urine for urine testing in long-term care residents?

5. What are the evidence-based guidelines regarding the interpretation of urine test results?

21

WHAT DOES THE EVIDENCE SAY?

6. What is the clinical evidence on the development of antibiotic resistance to norfloxaxin in treatment of urinary tract infections (UTIs)?

7. What is the clinical evidence regarding the

safety of nitrfurantoin in elderly males with urinary tract infections?

What does the evidence say?

8.What is the comparative clinical effectiveness of long-term antibiotic prophylaxis and treatment of urinary tract infections (UTIs) in the elderly?

9.What are the evidence-based guidelines

regarding the management of UTIs with antibiotics in the elderly?